fortune ox 2024

Regions Financial Corp. stock underperforms Friday when compared to competitors

Inari Medical Announces Reimbursement Approval for ClotTriever® Thrombectomy System in Japan ...‘Powerful’ Aussie chardonnay tops elite wine collectors’ hit parade

The NBA's Christmas Day lineup achieved its highest viewer ratings in five years, marking a significant milestone for the league. Each of the five games broadcasted on ABC, ESPN, ESPN2, Disney+, and ESPN+ garnered an average of 5.25 million viewers, reflecting an 84% increase from last year. Leading the day, a high-profile clash between NBA stars LeBron James and Stephen Curry drew in an impressive average of 7.76 million viewers. James's Los Angeles Lakers narrowly defeated Curry's Golden State Warriors 115-113. Moreover, the New York Knicks' win over the San Antonio Spurs marked the most-watched Christmas Day opener in over a decade. Despite new competition from the NFL's debut two games streaming on Netflix, the NBA's holiday games remained a beloved tradition for fans across more than 200 countries. James expressed confidence in the NBA's enduring Christmas appeal, stating, 'I love the NFL, but Christmas is our day.' (With inputs from agencies.)Peering Into Sysco's Recent Short Interest

Millions of university graduates and students will soon wake up to an early Christmas present after the government wiped thousands of dollars off their debts. or signup to continue reading Laws to cap the indexation rate for the Higher Education Loan Program at either the rate of inflation or the wage price index - whichever is lowest - passed federal parliament late Tuesday night after Australians were stung with a 7.1 per cent increase to their student debts in 2023 because of surging inflation. The indexation changes will lead to $3 billion in debt being cleared over coming weeks. "University is a lot more expensive today than when I was at university," Education Minister Jason Clare told reporters in Canberra on Wednesday. "Wiping $3 billion in debt will fix that spike in inflation that happened last year and it'll make sure that never happens again." People with an average HELP debt level will get a $1200 reduction on their loans. Those with a debt of $45,000 will get a decrease of about $2000, while students with $60,000 owning will have debt lowered by $2700. The changes were recommended in the university accords, a review of the tertiary education sector handed down in February. The laws mean university students completing placement will receive payments to help with living costs from July 2025. Students in degrees including teaching, nursing, midwifery and social work will receive an allowance of $319 per week. The reforms were a big win for students and graduates at a time when many Australians were struggling with the high cost of living, Universities Australia chief executive Luke Sheehy said. Though universities have celebrated these measures, other government proposals for the sector have been widely spurned. Labor has attempted to implement a cap on the number of foreign student arrivals from 2025. The reform would be used in place of an immigration rule known as ministerial direction 107, that has throttled student visas. Swinburne University of Technology vice-chancellor Pascale Quester has urged the government to replace the ministerial direction and prioritise visa processing for enrolments in science, technology, engineering and mathematics courses - collectively known as STEM subjects. The number of domestic students taking these courses has dropped steadily, while international student interest has increased by 39 per cent since 2021. "Forget a brain drain, we are at risk of a brain drought," Professor Quester said. "There is so much STEM talent in the region, but we have slammed the door in their faces with hastily-crafted policy." The government is also expected to slash a further 20 per cent off Australians' student debt if it wins the federal election in 2025. Advertisement Sign up for our newsletter to stay up to date. We care about the protection of your data. Read our . AdvertisementPM Manmohan Singh will always remain in the history of Indian politics as a debatable figure, whose contributions towards the world economy has been nothing short of phenomenal. On countless occasions, he has saved India as well its allies from severe economic crisis, and his efforts towards building Indo-US relations may have been criticized back then, but the Asian country is surely reaping the benefits of the same now, with a different Prime Minister at the helm. ET Year-end Special Reads Corporate Kalesh: Top family disputes of India Inc in 2024 The world of business lost these eminent people in 2024 Fast, faster, fastest: How 2024 put more speed into your shopping Did India-US relation building help both countries during former PM Manmohan Singh's regime? There is a lot of difference in opinion around the contribution of PM Singh towards the building of India-US relations. The 2008 nuclear deal takes the cake, but the ties with the United States still did not help the country in attaining a permanent seat in the UN Security Council back then. The Khobragade spat from back then had also severed the Washington-Delhi ties, with China, then and now, remaining a major challenge for India, with the US not doing much to help in talks between the two countries. Pakistan has always remained like a thorn to India's side, and the US has been rather volatile on the Indo-Pak concept, with each President adapting different strategies. Only in recent times has the US grown explicitly critical about Pakistan's military strategies, including the fact that it is now building long-range tactical nuclear missiles through its weapons development program. US' on-off pivot policy in Asia has created much of a problem for Delhi over the years, especially in Singh's tenure, and even though he tried, his government could not achieve much in this aspect. FAQs: When did PM Manmohan Singh passed away? PM Manmohan Singh passed away on December 26, 2024, after being admitted to a hospital in New Delhi. Artificial Intelligence(AI) Java Programming with ChatGPT: Learn using Generative AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Basics of Generative AI: Unveiling Tomorrows Innovations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Mastering C++ Fundamentals with Generative AI: A Hands-On By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Master in Python Language Quickly Using the ChatGPT Open AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Performance Marketing for eCommerce Brands By - Zafer Mukeri, Founder- Inara Marketers View Program Office Productivity Zero to Hero in Microsoft Excel: Complete Excel guide 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance A2Z Of Money By - elearnmarkets, Financial Education by StockEdge View Program Marketing Modern Marketing Masterclass by Seth Godin By - Seth Godin, Former dot com Business Executive and Best Selling Author View Program Astrology Vastu Shastra Course By - Sachenkumar Rai, Vastu Shashtri View Program Strategy Succession Planning Masterclass By - Nigel Penny, Global Strategy Advisor: NSP Strategy Facilitation Ltd. View Program Data Science SQL for Data Science along with Data Analytics and Data Visualization By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) AI and Analytics based Business Strategy By - Tanusree De, Managing Director- Accenture Technology Lead, Trustworthy AI Center of Excellence: ATCI View Program Web Development A Comprehensive ASP.NET Core MVC 6 Project Guide for 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital Marketing Masterclass by Pam Moore By - Pam Moore, Digital Transformation and Social Media Expert View Program Artificial Intelligence(AI) AI-Powered Python Mastery with Tabnine: Boost Your Coding Skills By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Mastering Microsoft Office: Word, Excel, PowerPoint, and 365 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital marketing - Wordpress Website Development By - Shraddha Somani, Digital Marketing Trainer, Consultant, Strategiest and Subject Matter expert View Program Office Productivity Mastering Google Sheets: Unleash the Power of Excel and Advance Analysis By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Mastering Full Stack Development: From Frontend to Backend Excellence By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Financial Literacy i.e Lets Crack the Billionaire Code By - CA Rahul Gupta, CA with 10+ years of experience and Accounting Educator View Program Data Science SQL Server Bootcamp 2024: Transform from Beginner to Pro By - Metla Sudha Sekhar, IT Specialist and Developer View Program How many terms did PM Manmohan Singh serve? PM Manmohan Singh served two terms as the Prime Minister of India, both the collision governments being known as UPA I and UPA II respectively. (You can now subscribe to our Economic Times WhatsApp channel )

Middle East latest: Ceasefire between Israel and Hezbollah in Lebanon is set to begin at 4 am

Paves way for additional large indications markets TORONTO and HAIFA, Israel, Dec. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing exosome-based regenerative therapies, has announced significant findings from an expanded preclinical study of the potential of its portfolio drug, ExoPTEN, for repairing optic nerve damage. Conducted in collaboration with the Goldschleger Eye Institute at Sheba Medical Center, consistently ranked one of the top ten hospitals in the world 1 , the study builds on previously announced preliminary results 2 on June 28, 2024 and strengthens the suggestion of a promising treatment pathway for glaucoma, the leading cause of irreversible blindness globally 3 . The Optic Nerve Disorders treatment market is expected to grow from 5.54 (USD Billion) in 2023 to 11.5 (USD Billion) by 2032, at a compound annual growth rate (CAGR) of ~8.46% during the forecast period 4 . Researchers utilized a rodent model of optic nerve crush (ONC) to simulate the damage associated with conditions like glaucoma. After inducing injury, ExoPTEN was administrated via direct injection into the eyes. The study expanded on earlier findings which indicated that eyes treated with ExoPTEN regained nearly normal retinal activity, as evidenced by electrical tests. Expanded analyses of the study data showed clear recovery of signal transmission in treated eyes compared to untreated controls, which showed no significant response. Additionally, imaging results by optical coherence tomography (OCT) scans indicates and validates that in all of treated eyes (naïve exosome treatment or ExoPTEN treatment) a successful ONC procedure has been performed (Figure 1). The study also showed that ExoPTEN treatment significantly enhanced the survival of retinal ganglion cells - key neurons responsible for transmitting visual information to the brain. Detailed analysis of retinal flat-mounts confirmed this effect, with treated eyes exhibiting substantially higher counts of these cells compared to untreated or control-treated eyes (Figures 2A and 2B). Dr. Ifat Sher, the lead investigator from the Goldschleger Eye Institute, commented, "the results from this expanded study are extremely encouraging. ExoPTEN demonstrates potential as a treatment that restores functionality and offers neuroprotection. The study shows clear signal recovery, healthier optic nerve structures and preserved retinal ganglion cells. These results suggest that ExoPTEN could fundamentally change how we approach conditions like glaucoma and optic nerve trauma. Encouraged by these results, we are advancing to a larger study with more animals to validate and expand upon these findings.” Dr. Lior Shaltiel, CEO of NurExone, added, "these findings are an important step forward in our mission to develop groundbreaking therapies for regenerative medicine in several indications. ExoPTEN's ability to repair both the structure and function of the optic nerve highlights its transformative potential for addressing vision loss and improving tens of millions of patient lives.” About NurExone NurExone Biologic Inc. is a TSX Venture Exchange (" TSXV ”) and OTCQB listed pharmaceutical company that is developing a platform for biologically guided exosome-based therapies to be delivered, minimally-invasively, to patients who have suffered Central Nervous System injuries. The Company's first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the United States Food and Drug Administration (FDA) and by the European Medicines Agency (EMA). The NurExone platform technology is expected to offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. For additional information and a brief interview, please watch Who is NurExone? , visit www.nurexone.com or follow NurExone on LinkedIn , X (formerly Twitter) , Facebook or YouTube Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: [email protected] Oak Hill Financial Inc. 2 Bloor Street, Suite 2900 Toronto, Ontario M4W 3E2 Investor Relations - Canada Phone: +1-647-479-5803 Email: [email protected] Dr. Eva Reuter Investor Relations - Germany Phone: +49-69-1532-5857 Email: [email protected] Allele Capital Partners Investor Relations - US Phone: +1 978-857-5075 Email: [email protected] FORWARD-LOOKING STATEMENTS This press release contains certain "forward-looking statements” that reflect the Company's current expectations and projections about its future results. Wherever possible, words such as "may”, "will”, "should”, "could”, "expect”, "plan”, "intend”, "anticipate”, "believe”, "estimate”, "predict” or "potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the results of the Company's preclinical trials and its suggestion of a promising treatment pathway for glaucoma; the growth of the Optic Nerve Disorders treatment market; the Company expanding to further studies; the Company developing groundbreaking therapies for regenerative medicine in several indications; ExoPTEN having the potential to address vision loss and improve patient lives; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including : the a bility to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the Company's ability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company's ability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine; the Optic Nerve Disorders treatment market continuing to grow as stated; the Company expanding to further studies; the Company developing groundbreaking therapies for regenerative medicine in several indications; ExoPTEN addressing vision loss and improve patient lives; and the NurExone platform technology will offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to : the Company's early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; dependence on the Company's strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company's intellectual property and technology won't have the intended impact on the Company and/or its business; the Company's inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the Company's inability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company's inability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine; the Optic Nerve Disorders treatment market decreasing and/or plateauing ; the Company 's inability to expand into further studies; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications ; and the risks discussed under the heading "Risk Factors” on pages 44 to 51 of the Company's Annual Information Form dated August 27 , 202 4 , a copy of which is available under the Company's SEDAR+ profile at www.sedarplus.ca . These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law. Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. 1 https://www.afsmc.org/2024/02/sheba-medical-center-named-a-newsweek-worlds-best-hospital-for-the-6th-consecutive-year/ 2 https://www.globenewswire.com/news-release/2024/06/28/2906122/0/en/NurExone-s-ExoPTEN-Being-Studied-as-Glaucoma-Treatment-for-US-3-4-Billion-Market.html 3 https://www.mdpi.com/1424-8247/17/10/1261 4 https://www.marketresearchfuture.com/reports/optic-nerve-disorders-treatment-market-30051 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5e682a60-3287-44b2-b7da-08ebed8fa807An undersea power cable that runs between Finland and Estonia was disconnected on Christmas Day. Finland is pretty sure that Russia is to blame. On Thursday, Finnish authorities boarded an oil tanker that is part of Russia’s “shadow fleet” used to dodge sanctions and that just so happened to be spotted passing over the EstLink 2 underwater cable as it stopped working, according to the Financial Times . Per The Guardian , the incident happened at 12:26 pm local time on Wednesday, and Arto Pahkin, Finland’s head of operations for the electricity grid, immediately said sabotage could not be ruled out. Finnish authorities have also confirmed that damage was caused to at least three other cables , potentially part of the same incident. This led to the seizure of Eagle S, an oil tanker registered to the Cook Islands but believed to belong to Russia. The ship’s tracking data suggests it was carrying oil from Russia to Egypt, but apparently made room to cause some chaos along the route. Authorities believe the ship’s anchor, which could not be found on the ship, was used to cut the cables. The Eagle S is believed by authorities to be part of Russia’s shadow fleet , which the country has been using since the start of its war with Ukraine to evade Western sanctions. The fleet consists of old, rickety vessels that Russia obscures its ownership of using a variety of techniques including labyrinthian management structures, frequent cargo transfers between vessels, falsified information, identification system blackouts, and other schemes. It’s believed the country operates about 600 ships as part of its off-the-books oil business. Because many of these ships carry oil and are poorly maintained, they often violate modern safety standards and ignore regulations, resulting in additional harm including oil spills . The Christmas Day cable cutting is just the latest in a series of incidents in which undersea cables connecting NATO countries have been severed. Last month, two fiber-optic cables in the Baltic Sea—one running between Finland and Germany, another connecting Lithuania and Sweden— were cut . Those, too, were believed to be the work of Russia’s shadow fleet, which has made a habit of hanging out near critical infrastructure in the Baltic and North Seas, according to the New York Times . While the attacks on these cables have yet to result in any tangible disruption, it has led to an uptick in concern about how this underwater infrastructure could be targeted in future conflicts. Reports have suggested that China has utilized similar tactics in the past, using boat anchors to damage undersea cables. It’s a relatively easy attack to carry out , as most of the cables are about as thick as a garden hose and sit exposed on the sea floor. Countries are exploring additional protections for these key pieces of connectivity to prevent future attacks.